ARVINAS, INC.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARVINAS, INC. | ||
| Date: February 24, 2026 | By: | /s/ Randy Teel, Ph.D. |
|---|---|---|
| Randy Teel, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Randy Teel, Ph.D. | President and Chief Executive Officer, Director | February 24, 2026 |
| Randy Teel, Ph.D. | (principal executive officer) | |
| /s/ Andrew Saik | Chief Financial Officer and Treasurer | February 24, 2026 |
| Andrew Saik | (principal financial officer) | |
| /s/ David K. Loomis | Vice President and Chief Accounting Officer | February 24, 2026 |
| David K. Loomis | (principal accounting officer) | |
| /s/ Briggs Morrison, M.D. | Chair of the Board of Directors | February 24, 2026 |
| Briggs Morrison, M.D. | ||
| /s/ Sunil Agarwal, M.D. | Director | February 24, 2026 |
| Sunil Agarwal, M.D. | ||
| /s/ Linda Bain | Director | February 24, 2026 |
| Linda Bain | ||
| /s/ Everett Cunningham | Director | February 24, 2026 |
| Everett Cunningham | ||
| /s/ John Houston, Ph.D. | Director | February 24, 2026 |
| John Houston, Ph.D. | ||
| /s/ Edward Kennedy, Jr. | Director | February 24, 2026 |
| Edward Kennedy, Jr. | ||
| /s/ Leslie Norwalk, Esq. | Director | February 24, 2026 |
| Leslie Norwalk, Esq. | ||
| /s/ Laurie Smaldone Alsup, M.D. | Director | February 24, 2026 |
| Laurie Smaldone Alsup, M.D. | ||
Index to Consolidated Financial Statements
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No.34) | F-2 |
|---|---|
| Consolidated Balance Sheets | |
| December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | |
| Years ended December 31, 2025, 2024 and 2023 | F-5 |
| Consolidated Statements of Changes in Stockholders’ Equity | |
| Years ended December 31, 2025, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows | |
| Years ended December 31, 2025, 2024 and 2023 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
F - 1
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.